Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)

Next Previous
X
Search
Trial Profile

A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gebasaxturev (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-200; STORM
  • Sponsors Viralytics

    • Most Recent Events

    • 14 Jan 2020 Status changed from active, no longer recruiting to completed.
    • 10 Sep 2019 Results assessing the efficacy of Pembrolizumab in combination with CVA21 in a preliminary cohort of 8 pre-treated NSCLC patients with secondary resistance to prior anti-PD-1/anti-PD-L1 therapy, presented at the 20th World Conference on Lung Cancer
    • 01 May 2019 Planned End Date changed from 1 Dec 2019 to 25 Dec 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top